Name | Value |
---|---|
Revenues | 4,257.0K |
Cost of Revenue | 2,117.0K |
Gross Profit | 2,140.0K |
Operating Expense | 2,999.0K |
Operating I/L | -859.0K |
Other Income/Expense | -25.0K |
Interest Income | 0.0K |
Pretax | -884.0K |
Income Tax Expense | 0.0K |
Net Income/Loss | -884.0K |
Precipio, Inc. is a healthcare solutions company in the United States, specializing in diagnostic blood cancer testing services. The company offers a range of products and services including IV-Cell, HemeScreen genetic diagnostic panels, ICE-COLD PCR technology, and COVID-19 antibody tests. It generates revenue through the sale of its proprietary cell culture media, genetic diagnostic panels, ICE-COLD-PCR technology kits, and COVID-19 antibody tests. Additionally, Precipio, Inc. collaborates with academic institutions focused on cancer research, diagnostics, and treatment, further enhancing its product offerings and market presence.